Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Aarhus University Hospital · Monash University · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
638
total citations
- FWCI
- 29.36
- Percentile
- 100%
- References
- 31
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Panobinostat
- Medicine
- Histone deacetylase inhibitor
- Antiretroviral therapy
- Human immunodeficiency virus (HIV)
- Clinical trial
- Virology
- Histone deacetylase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- GSGilead Sciences
- SFStrategiske Forskningsråd
- AUAarhus Universitet
- AUAarhus Universitetshospital
- AFAugustinus Fonden
- AFAIDS Fondet
- SSScandinavian Society for Antimicrobial Chemotherapy Foundation
- NINational Institutes of HealthAward: U19AI096109
- NHNational Health and Medical Research CouncilAward: 1009533
- NMNational Medical Research Council
- NINational Institute of Allergy and Infectious Diseases